If you have been looking into weight loss options recently, you may have come
across news of Wegovy Semaglutide Tablets, the daily pill version of the same semaglutide injection that
has become one of the most widely discussed weight loss medicines in recent years. The most
common question people have is simple: how much weight can you actually lose on it?
This guide covers what the clinical evidence shows, how the tablet compares to the Wegovy
injection, what factors influence individual results, and what a realistic timeline looks like.
Note that as of May 2026, Wegovy Semaglutide Tablets (oral semaglutide
25mg) are not yet approved in the UK, with the MHRA decision expected sometime in 2026. If you are
looking for a currently available Wegovy treatment, the weekly injection
is licensed and available now.
How Does Oral Semaglutide Cause Weight Loss?
Both the Wegovy injection and Wegovy Semaglutide Tablets contain the same active ingredient: semaglutide,
a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your body naturally
releases after eating. Semaglutide mimics its action, binding to GLP-1 receptors in the brain
and digestive system to reduce appetite, slow the rate at which your stomach empties, and
increase the feeling of fullness after meals.
The practical effect is that most people find it significantly easier to eat less without the
persistent hunger that makes calorie-restricted diets difficult to sustain. Semaglutide does
not burn fat directly or raise your metabolic rate. The weight reduction it produces comes from
a lower calorie intake.
The tablet reaches the bloodstream via a different route to the injection. Semaglutide is a
peptide and would normally be broken down by stomach acid before it could be absorbed. To
prevent this, every Wegovy Semaglutide Tablet contains an absorption enhancer called SNAC
(salcaprozate sodium), which temporarily protects semaglutide from stomach acid and opens a
pathway through the stomach lining. This is why Wegovy Semaglutide Tablets must be taken on
an empty stomach with a small amount of plain water (up to 4 ounces / 120ml), and nothing
else consumed for 30 minutes
afterwards. Food, other drinks, or oral medications interfere with SNAC and significantly
reduce how much semaglutide reaches your bloodstream. The PI also notes that absorption is
higher with smaller volumes of water, which is why the 4-ounce limit applies in both
directions.
What Did the OASIS-4 Trial Find?
The evidence for Wegovy Semaglutide Tablets comes primarily from the phase 3 OASIS-4 trial, published in
the New England Journal of Medicine in September 2025. The trial enrolled 307 adults without
diabetes who had a BMI of 30 or above, or a BMI of 27 or above with at least one
weight-related complication. Participants were randomly assigned to oral semaglutide 25mg once
daily or placebo, alongside lifestyle support including dietary and activity advice, for
64 weeks.1
The results depended on which statistical measure was used:
- With full treatment adherence (the per-protocol estimand), participants taking oral
semaglutide lost an average of 16.6% of their body weight by week 64, compared with 2.7%
in the placebo group.1
- Regardless of adherence (the treatment-policy estimand, which includes everyone who
started treatment), the average weight loss was 13.6%, compared with 2.2% in the placebo
group.1
The distinction matters. The 16.6% figure reflects what the medication can do when taken
consistently and correctly. The 13.6% figure reflects real-world conditions more closely,
accounting for participants who reduced their dose, paused treatment, or stopped altogether.
Both figures represent a meaningful treatment effect compared to placebo.
In terms of milestone outcomes among adherent participants:
- Around 34% lost 20% or more of their body weight
- Around 3% of placebo participants achieved the same
- A greater proportion in the semaglutide group also normalised their blood pressure,
fasting glucose, and lipid levels by the end of the trial
How Do Wegovy Semaglutide Tablets Compare to the Injection?
The Wegovy injection (semaglutide 2.4mg weekly) has its own body of clinical evidence from the
STEP trial programme. The STEP 1 trial, which enrolled 1,961 adults without diabetes, found an
average weight loss of 14.9% over 68 weeks with the 2.4mg weekly injection, compared with
2.4% on placebo.2
Putting the OASIS-4 and STEP 1 figures side by side gives a reasonable comparison, though the
trials were not designed to test one against the other directly. The treatment-policy result
for the tablet (13.6%) is slightly below the STEP 1 injection figure (14.9%). The
full-adherence figure for the tablet (16.6%) is higher, but this reflects differences in how
adherence was counted across the two trials rather than a true superiority of the pill.
An indirect comparison presented at ObesityWeek 2025 found that oral and injectable semaglutide
produced comparable weight loss and cardiometabolic outcomes when studied populations were
accounted for.3 Similar proportions of participants in each trial achieved 5%,
10%, 15%, and 20% or more body weight reduction.
The practical takeaway: the tablet and the injection are in the same clinical league for weight
loss. The tablet is not quite as potent as the injection milligram-for-milligram, given that oral
bioavailability is approximately 1–2%, but the weight outcomes
are close enough that the choice between them is more likely to come down to convenience and
personal preference than efficacy.
For context, Mounjaro (tirzepatide), the dual GLP-1 and GIP receptor
agonist, produced greater average weight loss in its pivotal trial (20.9% over 72 weeks in
the SURMOUNT-1 trial).4 This reflects the additional mechanism of targeting the
GIP receptor alongside GLP-1.
How Much Weight Can You Lose in Practice?
Clinical trial averages describe a population, not an individual. The range of outcomes in the
OASIS-4 trial was wide, with some participants losing substantially more than the average and some
lost less.
Several factors influence individual response to oral semaglutide:
- Adherence to dosing rules - Because the tablet's absorption depends on the SNAC
mechanism, taking it with food or drink significantly reduces how much semaglutide enters
your bloodstream. Consistent fasting before each dose is one of the most controllable
factors in how well the tablet works.
- Completing dose escalation - Wegovy Semaglutide Tablets are prescribed at progressively
increasing doses, starting at 1.5mg and escalating to 25mg over several months, with each
increase every 30 days. People who stop escalation or reduce their dose due to side effects will
see lower average weight loss than those who reach and maintain the full 25mg dose.
- Diet and physical activity - All participants in the OASIS-4 trial received lifestyle
support alongside medication. Semaglutide is licensed as an adjunct to a reduced-calorie
diet and increased physical activity, not as a standalone treatment. The medication makes
it easier to eat less; it does not replace the need to do so.
- Diabetes status - People without type 2 diabetes consistently achieve greater weight
loss with semaglutide than those with the condition. All OASIS-4 participants were
non-diabetic, so the 13.6-16.6% figures apply specifically to this group.1
- Sex - Across multiple semaglutide trials, women have on average achieved slightly
greater percentage weight loss than men, though the medication is effective in both
sexes.5
How Long Does It Take to See Results?
In the OASIS-4 trial, weight loss began within the first few weeks of treatment and continued
progressively through the dose escalation period. Per the dosing schedule, patients begin the
maintenance dose of 25mg at day 91 of treatment, roughly the start of the fourth month.
Weight loss typically accelerates once the full dose is reached and tends to plateau somewhere
between months 12 and 16. Most of the total weight reduction achievable with oral semaglutide
will have occurred by week 64, which is why the trial ran to that endpoint.
Early on, the effect is subtler: a noticeable reduction in appetite and a greater feeling of
fullness after smaller meals. Measurable weight change follows from these shifts in eating
behaviour rather than from any acute pharmacological effect on fat tissue.
Who Are Wegovy Semaglutide Tablets Suitable For?
Based on the licensed indication approved by the FDA in December 2025, Wegovy Semaglutide Tablets
are indicated for adults with obesity, or adults with overweight who have at least one weight-related
comorbid condition. This mirrors the eligibility criteria for the Wegovy injection
in the UK. MHRA approval for the tablet is expected in late 2026, at which point UK eligibility
criteria will be confirmed. You can register your interest now on the
Wegovy oral tablet page.
Wegovy Semaglutide Tablets are contraindicated in people with a personal or family history of
medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), and in
those with a known serious hypersensitivity to semaglutide. The tablet is not recommended during pregnancy
or breastfeeding. People with type 2 diabetes should discuss with their prescriber whether
the tablet or injection is more appropriate, as the PI notes that semaglutide blood concentrations
from the tablet are lower in people with type 2 diabetes than in those without, which may result
in a reduced treatment response compared to the injection.
When to Seek Further Advice
Speak to your GP or prescribing clinician if you:
- Are not seeing any weight reduction after completing dose escalation to 25mg
- Experience persistent or severe nausea, vomiting, or abdominal pain
- Develop symptoms that could indicate pancreatitis: persistent or severe abdominal pain,
sometimes radiating to the back, with or without nausea or vomiting. Discontinue the
medication and seek medical attention without delay.
- Have concerns about how other medications you take may interact with oral semaglutide,
as the tablet's delay of gastric emptying can affect the absorption of other oral medicines
- Are considering starting treatment for the first time and want to discuss whether the
tablet or injection would be more appropriate for your situation
Frequently Asked Questions
Is the Wegovy pill as effective as the injection?
Clinical trial data shows they are closely comparable. In the OASIS-4 trial, Wegovy Semaglutide Tablets produced an average of 13.6% body weight loss over 64 weeks (based on
all participants regardless of adherence), rising to 16.6% among those who took the full
dose consistently. The Wegovy injection (2.4mg weekly) produced an average of 14.9% over
68 weeks in the STEP 1 trial. An indirect comparison of both trials found similar
proportions of participants achieving 5%, 10%, 15%, and 20% or more body weight reduction.
The tablet is a meaningful alternative for people who prefer not to use injections, with
weight outcomes in the same clinical range.
Do Wegovy Semaglutide Tablets work for weight loss?
Yes. Wegovy Semaglutide Tablets (oral semaglutide 25mg) are a licensed treatment for
weight management in adults, backed by the phase 3 OASIS-4 trial published in the New
England Journal of Medicine. Participants taking the tablet alongside diet and activity
support lost an average of 13.6-16.6% of their body weight over 64 weeks, compared with
around 2% in the placebo group. As with any weight loss medicine, results are greater when
combined with a reduced-calorie diet and increased physical activity.
How long does it take for Wegovy Semaglutide Tablets to work?
Weight loss with Wegovy Semaglutide Tablets begins within the first few weeks of
treatment, but the full effect builds gradually over several months. The dose escalates
every 30 days, starting at 1.5mg and reaching the maintenance dose of 25mg at day 91 of
treatment. Most of the total weight reduction seen in clinical trials had occurred by week
64. Results are typically most noticeable once you reach and have been on the full 25mg
maintenance dose, which is when the medication is working at its intended level.
Is Wegovy a pill or an injection?
Wegovy is now available in both forms. The Wegovy injection (semaglutide 2.4mg) is
administered once weekly using a prefilled pen, and is the currently licensed option in
the UK. Wegovy Semaglutide Tablets (oral semaglutide 25mg) are taken once daily and were
approved by the FDA in December 2025. The tablet is not yet approved by the MHRA for use
in the UK, with a decision expected sometime in 2026. Both forms contain the same active
ingredient, semaglutide, and work through the same mechanism.
Do Wegovy Semaglutide Tablets affect the contraceptive pill?
Wegovy Semaglutide Tablets slow gastric emptying, which can affect how quickly other
oral medications pass through the stomach and are absorbed. In a drug interaction study,
the absorption of levothyroxine was increased when taken alongside Wegovy Semaglutide Tablets.
No clinically significant interaction was found with ethinyl estradiol or levonorgestrel,
the hormones used in most combined oral contraceptives. However, because the tablet can
affect the absorption of some oral medicines, you should tell your prescribing clinician
about all medications you are taking, including contraceptives, before starting treatment.
What percentage of body weight can you lose on Wegovy Semaglutide Tablets?
In the OASIS-4 trial, participants who took the full 25mg maintenance dose consistently
lost an average of 16.6% of their starting body weight over 64 weeks. Among those
participants, around one in three achieved 20% or more body weight reduction. For all
participants in the trial, including those who reduced or stopped their dose, the average
was 13.6%. Individual outcomes vary depending on adherence to dosing rules, diet and
physical activity, and other personal factors.
References
- Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of
25 mg in Adults with Overweight or Obesity. New England Journal of Medicine.
2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in
Adults with Overweight or Obesity. New England Journal of Medicine.
2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Novo Nordisk. OASIS 4 indirect comparison: oral and injectable semaglutide
comparable outcomes in weight reduction and cardiometabolic measures. Presented at
ObesityWeek 2025, Atlanta, November 4-7, 2025.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for
the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
doi:10.1056/NEJMoa2206038
- Strathe AV, Fors JJ, Frandsen CS, et al. A model-based approach to predict
individual weight loss with semaglutide in people with overweight or obesity. Diabetes,
Obesity and Metabolism. 2023;25(9):2487-2496.
doi:10.1111/dom.15211
This article is intended for informational purposes only and does not replace professional
medical advice. Always read the patient information leaflet supplied with your medication and
speak to a healthcare professional if you have specific concerns.